Search papers, labs, and topics across Lattice.
2
0
0
1
T-DXd demonstrates similar real-world effectiveness in HER2+ metastatic breast cancer patients regardless of the presence or activity status of brain metastases.
Earlier use of trastuzumab deruxtecan (T-DXd) in the second-line setting for HER2+ metastatic breast cancer is associated with improved duration of therapy, progression-free survival, and overall survival compared to later-line use.
